The recent introduction in the clinical practice of mTOR inhibitors and, mainly, sorafenib, as molecular therapies against HCC, has focalized on the attention on new plasma biological markers [71, 72]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.